top of page
.png){kind=small}
Stabilizing the Nervous System.
Personalizing the Taper.
Common Questions About Care
Answers about how the taper is paced, what happens when symptoms change, who prescribes, what care costs, and whether the program may be right for you.
How
Care
Works
Patients come to us at many different stages. Some have not yet begun tapering and want to develop a careful plan. Many are already partway through a taper and have become less stable after reductions that were too large or too frequent. Others are holding at their current dose, considering a transition from a shorter-acting benzodiazepine, or are already off the medication but continue to have significant symptoms.A common theme is that patients either have developed significant symptoms during a taper or are afraid to begin because of difficult withdrawal experiences they have read about online. In both situations, care focuses on the patient's actual clinical state and provides a structured plan for stabilization, monitoring, and gradual dose reduction.Care with us has three main features.Stabilization comes before dose reduction. We first review your medication pattern, symptoms, medical history, sleep, nutrition, activity, and other factors that may be affecting clinical stability. The early plan may include making the dose and dosing times more consistent, supporting sleep and regular meals, addressing modifiable contributors, and avoiding several treatment changes at once. A dose reduction is introduced when there is enough stability to tolerate the next step.Tapering is individualized. We combine your preferences with Dr. Madhava's clinical guidance, and we allow enough time to observe your response before deciding what comes next.Care is month-to-month. There is no annual contract or full-year payment in advance, and you may stop before your next monthly payment is due.
You will receive a clear plan, but not a calendar that specifies every reduction between your current dose and zero.Before each dose change, we confirm your current dose and schedule, agree on the next proposed step, decide when to reassess, and identify what we will monitor. We do not map out every reduction in advance because your response to each change helps determine what comes next.Sleep disruption, illness, stress, medication changes, and the cumulative effect of earlier reductions can all change what you can tolerate at a particular time. A schedule written far in advance cannot respond to those changes.The clinical process is structured; the pace remains responsive. A hold, a smaller next reduction, or a longer interval may be part of the plan, not a departure from it.In other words: you will always know the plan for the next step, even though we don't map out every step to zero in advance.
The pace is based on your current clinical state, not on the medication dose alone. We consider the intensity and stability of your symptoms, your day-to-day functioning, and factors that may affect your ability to tolerate another change.The goal is not necessarily to eliminate every symptom before proceeding. It is to keep each change within a range your nervous system can adapt to while maintaining overall stability. You may still have symptoms, but their pattern, intensity, and effect on sleep and daily functioning help determine whether you are ready for another reduction.Published guidance describes reductions of approximately 5–10% every two to four weeks as a general starting range, not a schedule for every patient. In this practice, we often begin with a smaller reduction and allow more time to observe the response, particularly after long-term use or previous difficulty tapering.A taper may take many months, and for some patients longer than a year. Someone with relatively brief exposure and few symptoms may be able to proceed faster. We adjust the pace collaboratively based on your response — not on the starting dose alone.You will never be asked to commit to a pace in advance.
We generally pause further reductions and assess what changed. We look at the timing and pattern of the symptoms, along with sleep, daily functioning, illness, stress, activity, nutrition, medication changes, and whether symptoms emerge before the next dose.A flare may indicate that the reduction was too large or too close to the previous one, or that other factors are adding to the person's overall symptom burden. We consider whether the recent change exceeded the range within which the nervous system can adjust and maintain stability. We do not assume that every new or worsening symptom is caused by withdrawal; unfamiliar, severe, or concerning symptoms may require local medical evaluation.We usually make one change at a time and allow enough time to understand the response. The next step may be:a longer hold,a smaller subsequent reduction,a change in dosing method, oranother adjustment to the plan.A hold is not a failure. It is an active part of managing the taper.
Not entirely. Dr. Ashton's work has been enormously important in recognizing benzodiazepine withdrawal and in establishing the principle of gradual tapering. We share that foundation.However, we do not follow the Ashton method exactly. Two differences are worth noting. First, we do not automatically switch patients to diazepam. A diazepam switch is one option, not a requirement, and it is not appropriate for everyone. Second, the dose reductions described in the Ashton manual may be too fast for many patients, particularly after long-term use or previous difficulty tapering.In this practice, we often begin with smaller reductions and allow more time to observe the response.
Yes. Many patients come to us partway through a taper. We review your history, current dose, and symptoms, and develop a plan from where you are now.If you are currently working with another prescriber, we will coordinate any transition in prescribing or clinical responsibility, with your permission, as needed. This helps avoid conflicting taper plans or benzodiazepine prescriptions from more than one clinician.
The Five-Axis Stress Biology Framework™ is a clinical model developed by Dr. Madhava. It organizes withdrawal symptoms into five broad, overlapping categories, which can help make sense of the many different symptoms a person may experience.It is a clinical model. It does not prove which mechanisms are operating in any individual patient.
Dose
and
Medication
Options may include lower-strength tablets, carefully divided tablets when appropriate, or pharmacy-compounded capsules or liquids.The method depends on the medication, current dose, available formulations, and the patient's ability to measure and take each dose consistently. The approach may change as the dose becomes lower.If compounding is used, we work with a licensed compounding pharmacy.
No. Switching to diazepam is a possible option, not a requirement, and may not be appropriate for everyone.It may be considered when a longer-acting medication or access to smaller dose increments offers a practical advantage — for example, when symptoms repeatedly emerge before the next dose of a shorter-acting benzodiazepine. It may offer little advantage when someone is stable and already tolerating a gradual taper on the current medication.Switching medications introduces another clinical variable. Dose-equivalence estimates are approximate, and some patients do not tolerate the transition well. If a transition is appropriate, it is planned and monitored carefully.
When clinically appropriate and legally permitted, Dr. Madhava prescribes the benzodiazepine and manages the taper directly. This keeps the clinical assessment, the taper plan, and the prescription under the same physician's care.The dose and timing are decided collaboratively and adjusted according to your response. Prescribing is coordinated with scheduled clinical follow-up.If prescribing is not legally permitted in your location, we will discuss this during screening and explain what care we can and cannot provide.
Who the Program
Is For
Potentially, yes. Some patients come to us after discontinuation because significant symptoms have continued.Prolonged symptoms after benzodiazepine discontinuation are real and can be profoundly disabling for a subset of patients. At the same time, "protracted withdrawal" describes a time course; it does not establish that every ongoing symptom has a single cause or underlying mechanism.Support focuses on reducing destabilizing inputs, protecting sleep, establishing consistent nutrition and hydration, pacing physical and cognitive activity, gradually rebuilding function, treating specific symptoms when appropriate, and avoiding repeated medication changes that can make the clinical picture harder to interpret.
This program may be a good fit if you:Are medically and psychiatrically stable enough for outpatient care—for example, you do not currently need hospitalization or crisis services.Want a gradual, individualized taper rather than rapid discontinuation.Can participate consistently in appointments and agreed-upon plans.Have appropriate local medical and psychiatric care for needs outside the taper program.Have a reliable adult support person living with you who can participate at the level established during the Inquiry Meeting.Are willing to work on sleep, routine, nutrition, pacing, and other factors that influence stability—not just medication changes.Fit is determined through screening and the Inquiry Meeting, not by any one item alone.
We consider the whole picture, including other medical and psychiatric conditions. This program focuses on your taper and taper-related stabilization. It does not replace primary care or psychiatric care, so you will need a local provider who manages your other conditions. With your permission, we can coordinate with them as needed.
This is not the right program if you need detoxification, emergency or inpatient treatment, continuous monitoring, crisis intervention, primary care, hands-on rehabilitation, or another level of care that cannot be provided by telemedicine.It is also not designed for rapid discontinuation, a guaranteed pace or completion date, or a one-time medication recommendation without ongoing participation in care.We would rather identify that before you have spent money enrolling. If the program is not the right fit, we will tell you directly and, when possible, point you toward other resources or levels of care.
Our focus in this program is benzodiazepine tapering and stabilization. We review all medications and supplements for interactions or factors that may affect stability, but we do not manage unrelated medications. If you are looking for broader nervous-system stabilization work, Dr. Madhava also offers care through Brain Body Medical.
Telemedicine and
Support
Care is provided primarily by telemedicine. We work with patients in multiple U.S. states and with some patients outside the United States.The type of care we can provide — including whether Dr. Madhava can prescribe — depends on where you are physically located and the medical and prescribing regulations that apply in that location.In some locations, Dr. Madhava may be able to provide clinical guidance and stabilization planning even if she cannot prescribe. Eligibility is confirmed during screening before the Inquiry Meeting.
You do need established local medical care, and psychiatric care when appropriate, for needs outside the taper program. We will ask for the name and contact information of your local provider during screening.This program manages the benzodiazepine taper and related stabilization. It does not replace primary care, urgent care, emergency care, or the hands-on assessment of new medical symptoms.Some symptoms that arise during a taper need to be medically evaluated rather than automatically attributed to withdrawal. A local provider should assess new, severe, or unfamiliar symptoms. If you believe something may be dangerous or require immediate attention, call emergency services or go to the nearest emergency department.
Because this is intensive outpatient care delivered primarily by telemedicine, each patient must have a reliable adult living with them throughout care who is willing to participate when needed. The support person attends the Inquiry Meeting, and we discuss the expected level of involvement during screening.The support person is not there to speak for you or police the taper. Your own account remains central. Their role is to support safety and continuity when symptoms affect day-to-day function, help with practical needs when necessary, understand the care plan, and know when local or emergency help may be needed.With your permission, an additional perspective can also help the clinical team understand changes in sleep, function, or stability over time. If you cannot arrange the required support, the program may not be the right fit right now.
If symptoms become severe or you feel unsafe, contact your local provider, urgent care, or emergency services right away. This program is not an emergency service and does not provide continuous or 24-hour physician availability.Benzodiazepine withdrawal can bring periods of intense distress, including thoughts of self-harm. These experiences are not a sign of weakness or that you have done something wrong. If you are having them, please tell someone right away—your local provider, a person you trust, or, in the United States, the 988 Suicide & Crisis Lifeline by call or text.We will work with you and your local providers to coordinate care when possible, but you must meet urgent and emergency needs locally.
Life events, illness, and travel can affect care. We will discuss scheduling and any needed adjustments during your visits. Care is month-to-month, so you are not locked into a long contract. If you will be away or unable to attend visits for a period, let us know in advance so we can plan accordingly.
Daily Life
and
Duration
Program
Costs
The practice is private-pay and out-of-network. We do not participate with commercial insurance, Medicare, or Medicaid.The program provides ongoing physician-led assessment, stabilization planning, taper management, prescribing when clinically appropriate and legally permitted, and plan adjustments based on the patient's response. Appointment frequency, physician access, and additional services depend on the program selected and the phase of care.We have three program options: Core Care, Enhanced Care, and Concierge Care. Most patients choose Core Care.Core Care is $2,000 per month for the first two months during initial stabilization, then $1,000 per month for patients who are sufficiently stable to transition to shorter weekly visits; those who continue to need longer visits remain at $2,000 per month.Care is month-to-month, with no annual contract, and you may stop before your next monthly payment is due.
Before You
Begin
Many patients are unsure. Readiness is determined collaboratively. We assess your current stability, symptom burden, and support system. Some patients need a period of stabilization before any dose reduction; others are ready to begin tapering sooner.If you are unsure, that is a normal place to start. Readiness is something we assess together, not something you need to determine on your own before reaching out.
Care begins with stabilization, not necessarily with an immediate dose reduction.Consistency matters. Take the medication at the agreed-upon times, avoid changing several medications or supplements at once, protect sleep, eat regularly, and observe the response to each reduction without making additional changes in response to every difficult day.The goal is not to taper as slowly as possible or as quickly as possible. It is to move at a pace your nervous system can absorb while preserving as much sleep, function, and physiologic stability as possible.Symptoms can fluctuate, and recovery is rarely a straight line. Needing to hold does not mean the taper has failed. Reaching zero may be an important milestone, but it is not the only measure of progress. The larger goal is to regain stability and function while reducing medication safely.Before your first visit, it helps to gather your medication history, a list of current providers, and a record of your current dose and dosing times.
Next
Steps
If you are interested in joining the program, please contact us through the contact page. You will receive the Working With Us guide, which explains the program options and current fees.After that, prospective patients complete a screening form, provide relevant records and medication history, and watch Dr. Madhava's introductory talk. The next step is a 30-minute Inquiry Meeting with Dr. Madhava. The meeting fee is $200 and is credited in full toward the first monthly payment if you enroll within 14 days. Your support person attends with you.The Inquiry Meeting is used to determine whether the program is an appropriate fit. It is not a treatment visit and does not include medication changes, prescriptions, or an individualized taper plan.We know this is a significant cost and that it is not possible for everyone. Before scheduling the Inquiry Meeting, you will receive current pricing and a detailed description of what each program includes.
Where to start:
Dr. Madhava's introductory talk explains how the nervous system is affected during benzodiazepine withdrawal and why symptoms can change over time. It is free to watch, whether or not you go any further.
If you would like to explore working together, the next step is to request the Working With Us guide.
bottom of page